HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.